• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Crit Care . Spontaneous pneumomediastinum: a surrogate of P-SILI in critically ill COVID-19 patients

tetano

Editor, Senior Moderator
Crit Care


. 2022 Nov 12;26(1):350.
doi: 10.1186/s13054-022-04228-1.
Spontaneous pneumomediastinum: a surrogate of P-SILI in critically ill COVID-19 patients


Alexandre Elabbadi[SUP] 1 [/SUP], Tomas Urbina[SUP] 2 [/SUP], Enora Berti[SUP] 3 [/SUP], Damien Contou[SUP] 4 [/SUP], Gaëtan Plantefève[SUP] 4 [/SUP], Quintana Soulier[SUP] 2 [/SUP], Audrey Milon[SUP] 5 [/SUP], Guillaume Carteaux[SUP] 3 [/SUP], Guillaume Voiriot[SUP] 6 [/SUP], Muriel Fartoukh[SUP] 6 [/SUP], Aude Gibelin[SUP] 6 [/SUP]



Affiliations

Abstract

Spontaneous pneumomediastinum (SP) has been described early during the COVID-19 pandemic in large series of patients with severe pneumonia, but most patients were receiving invasive mechanical ventilation (IMV) at the time of SP diagnosis. In this retrospective multicenter observational study, we aimed at describing the prevalence and outcomes of SP during severe COVID-19 with pneumonia before any IMV, to rule out mechanisms induced by IMV in the development of pneumomediastinum.Among 549 patients, 21 patients (4%) developed a SP while receiving non-invasive respiratory support, after a median of 6 days [4-12] from ICU admission. The proportion of patients requiring IMV was similar. However, the time to tracheal intubation was longer in patients with SP (6 days [5-13] vs. 2 days [1-4]; P = 0.00002), with a higher first-line use of non-invasive ventilation (n = 11; 52% vs. n = 150; 28%; P = 0.02). The 21 patients who developed a SP had persisting signs of severe lung disease and respiratory failure with lower ROX index between ICU admission and occurrence of SP (3.94 [3.15-5.55] at admission vs. 3.25 [2.73-4.02] the day preceding SP; P = 0.1), which may underline potential indirect signals of Patient-self inflicted lung injury (P-SILI).In this series of critically ill COVID-19 patients, the prevalence of SP without IMV was not uncommon, affecting 4% of patients. They received more often vasopressors and had a longer ICU length of stay, as compared with their counterparts. One pathophysiological mechanism may potentially be carried out by P-SILI related to a prolonged respiratory failure, as underlined by a delayed use of IMV and the evolution of the ROX index between ICU admission and the day preceding SP.

Keywords: Coronavirus disease 2019; Intensive care unit; Pneumomediastinum; Pneumonia.
 
Back
Top Bottom